Personalize My Treatment (PMT) Registry (PMT)

February 3, 2025 updated by: Exactis Innovation

A Large-scale Longitudinal Oncology Registry

The 'Personalize My treatment' (PMT) platform is a novel form of biobanking in which cancer patients willingly consent to provide residual, clinical samples (surplus after diagnostic testing) of their tumors for cancer research, to give access to their medical record for data collection and then followed prospectively throughout the trajectory of their illness. They further willingly consent to be recontacted for being informed of other research projects, including clinical trials.

Study Overview

Status

Suspended

Conditions

Study Type

Observational

Enrollment (Estimated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N2
        • Tom Baker Cancer Centre
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Cross Cancer Institute
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1C 6Z8
        • The Moncton Hospital
      • Moncton, New Brunswick, Canada, E1C 2Z3
        • Centre Hospitalier Universitaire Dr-Georges-L.-Dumont
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 1V8
        • QE II Health Sciences Centre
    • Ontario
      • London, Ontario, Canada
        • London Health Science Centre
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital
      • Toronto, Ontario, Canada, M4N 3M5
        • Odette Cancer Centre - Sunnybrook Hospital
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Jewish General Hospital
      • Montreal, Quebec, Canada, H2X 0A9
        • Centre Hospitalier de l'Université de Montréal
      • Montreal, Quebec, Canada, H4A 3J1
        • MUHC McGill University Health Center
      • Québec, Quebec, Canada, H3T 1Y6
        • Centre hospitalier universitaire de Québec - Université Laval
      • Sherbrooke, Quebec, Canada, J1G 2E8
        • Centre Hospitalier Universitaire de Sherbrooke
      • Trois-Rivières, Quebec, Canada, G8Z 3R9
        • CIUSSS de la Mauricie-et-du-Centre-du-Québec - Centre Hospital Régional

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Cancer patients with all solid tumor types.

Description

Age of majority in the province of recruitment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The primary objective of PMT is to create a collection of cancer patient biospecimens and annotated data that will be used for clinical trial matching and to advance cancer research.
Time Frame: Longitudinal
Longitudinal

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Exactis Innovation

Investigators

  • Study Director: David Bouffard, PhD, Exactis Innovation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2015

Primary Completion (Actual)

December 13, 2024

Study Completion

July 1, 2025

Study Registration Dates

First Submitted

January 30, 2015

First Submitted That Met QC Criteria

January 30, 2015

First Posted (Estimated)

February 4, 2015

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 3, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • PMT

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The BDAC (Biospecimen and Data Access Committee) authorizes access requests from researchers to the PMT Platform's biospecimens and data. It meets as needed to review requests in accordance with the PMT Biospecimen and Data Access Policy. Requests will be evaluated based on scientific merit, availability of sample and alignment with the mission of the PMT Platform and Exactis. BDAC is responsible for verifying that the proposed project has received appropriate ethics approval and proof of such approval has been provided.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe